Commentary
Kidney International (2015) 88, 1223–1226; doi:10.1038/ki.2015.300
- 1Centre for Kidney Disease Research, School of Medicine, University of Queensland, Brisbane, Australia
- 2Translational Research Institute, Brisbane, Australia
- 3Nephrology Center, The Second Clinical College, Guangzhou University of Chinese Medicine and Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China
Correspondence: Glenda C.
Gobe, University of Queensland – Centre for Kidney Disease Research,
Translational Research Institute, 37 Kent Street, Woolloongabba,
Brisbane, Queensland 4102, Australia. E-mail: g.gobe@uq.edu.au
Top of page
ABSTRACT
The worth of traditional Chinese herbal medicines for chronic kidney disease (CKD) patients remains in debate. Lin et al.
used a research database in Taiwan to identify almost 25,000 stage 3–5
newly diagnosed CKD patients who, after diagnosis, did or did not use
prescribed Chinese herbal medicines for CKD. Reduced risk of end-stage
kidney disease from specific traditional medicines warrants reflection
on a CKD therapy resource that is largely ignored by Western medicine.
Current conventional-medicine
treatment options for chronic kidney disease (CKD) are limited in
efficacy, and often do not inhibit progression of CKD to end-stage
kidney disease (ESKD), an increasing and costly disease in many
societies. Nonetheless, there is continuing concern in Western medicine
about the value of traditional Chinese herbal medicines as treatments
for patients with CKD. Many active components of traditional-medicine
formulas are unknown, and their potential toxicities have not yet been
resolved. Since the disastrous use of plants with aristolochic acid
content (for example, Aristolochia fangchi) in some therapies for weight loss at clinics in Belgium in the early 1990s,1
where rapidly progressive fibrosing interstitial nephritis and
urothelial malignancies developed in treated women, Chinese herbal
medicine has been regarded by many Western clinicians with extreme
caution. More recently, in an attempt to free the use of traditional
Chinese herbal medicines from links, in general, with renal impairment,
use of the term ‘Chinese herbs nephropathy’ has been replaced with a
more specific descriptor of ‘aristolochic acid-associated nephropathy.2
It must be recognized, however, that traditional Chinese herbal
medicine forms part of a compendium of drugs offered to CKD patients in
many Asian countries. In addition, many patients in the West seek out
alternative therapies such as herbal medicines. Thus, the irrefutable
use of Chinese herbal medicines suggests the need for practitioners to
keep abreast of the most recent information about those therapies. Lin et al.3
(this issue) present information from a large Taiwan National Health
Insurance Research Database study that links some Chinese herbal
medicines with reduced risk of ESKD in patients with CKD.
Although in vitro
and preclinical animal studies often indicate therapeutic benefits of
Chinese herbal medicine in models of CKD, convincing evidence for or
against Chinese herbal medicine for patients with CKD is limited. A
summary of recent advances in traditional Chinese medicine for kidney
disease in two publications by Zhong et al.4, 5
suggests that evidence is often limited by the small size and limited
power of trials that are carried out. A clear limitation for advancing
use of Chinese herbal medicines is the real need to increase our
knowledge of the active ingredients and mechanism of action of the
herbal medicines. More research is needed, something that is now
occurring in China with recent increased research funding in the field
of traditional medicines and an increasing need for alternative
treatments for CKD patients.5 The report by Lin et al.3
is an exception to the small group studies. They used the Taiwan
National Health Insurance Research Database to identify almost 25,000
stage 3–5 newly diagnosed CKD patients, who, after diagnosis, did or did
not partake of a broad range of prescribed Chinese herbal medicines for
CKD. The results should cause us to reflect on a resource of CKD
therapies that is, still, often dismissed by Western medicine.